Full-Time
Vevo Therapeutics
11-50 employees
Biotechnology firm enhancing drug discovery using AI
No salary listed
Junior
San Bruno, CA, USA
Hybrid position requiring in-office presence.
Get referrals →
You have ways to get a Vevo Therapeutics referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 1 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
- Single-cell bioinformatics on large atlas datasets
- Machine learning applied to genomics data and cheminformatics
- High throughput synthetic lethal oncology genomics screens and subsequent target validation of individual genes
- Junior Scientists with tissue culture, single-cell sample preparation, laboratory automation using robotics, and biochemical assays for target validation and mechanistic investigation
- Medicinal chemistry, particularly in small molecule oncology
Vevo Therapeutics uses advanced AI models and its Mosaic platform to enhance drug discovery by generating high-resolution in vivo data, which studies drug interactions within living organisms. This method allows them to identify new drug targets and candidates that traditional approaches might miss. They serve pharmaceutical companies and research institutions by providing insights into drug efficacy and gene expression at a single-cell level, making the drug discovery process faster and more cost-effective. The company's goal is to uncover better drugs for a wider range of patients.
Company Size
11-50
Company Stage
Seed
Total Funding
$12M
Headquarters
San Francisco, California
Founded
2022
Simplify's Take
What believers are saying
- Partnership with Parse Biosciences boosts AI-powered drug discovery capabilities.
- $12M seed funding supports scaling operations and enhancing the Mosaic platform.
- Growing demand for single-cell RNA profiling increases pharmaceutical interest in Vevo's services.
What critics are saying
- AI models risk obsolescence without continuous innovation and updates.
- Increased competition from new AI-driven drug discovery startups threatens market share.
- Data privacy concerns could lead to stricter regulations affecting operations.
What makes Vevo Therapeutics unique
- Vevo's Mosaic platform offers high-resolution in vivo data for drug discovery.
- Their AI models analyze drug interactions within living organisms, not isolated cells.
- Vevo's single-cell RNA profiling reveals drug actions across diverse patient populations.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Unlimited Paid Time Off
Health Insurance
Dental Insurance
Vision Insurance
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↑ 0%2 year growth
↑ 4%Vevo Therapeutics has officially released the Tahoe-100M, described as the world's largest single-cell dataset, in collaboration with the Arc Institute.
Vevo Therapeutics partners with the Parse Biosciences GigaLab to generate 100M cell atlas for AI powered drug discovery.
Vevo Therapeutics, an SF-based biotechnology company, launched today with a $12M seed round led by General Catalyst and Wing Venture Capital using its Mosaic in vivo drug discovery platform and next-generation AI models to uncover better drugs for more patients.
Vevo Therapeutics, a biotechnology company using its Mosaic in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients, launched today with an oversubscribed and upsized $12M seed financing round.